RCPHF News and Press, Recipharma AB - Ordinary Shares - Class B

Investors are pricing a high probability that MRNA will introduce one or two blockbuster therapies to the market on top of the COVID vaccine. MRNA's pipeline focuses on diseases with high prevalence and unmet medical needs, increasing the chances of achieving commercial success. H...

Coronavirus vaccine makers have quickly turned to a network of smaller, lesser-known manufacturers to mount an unprecedented effort to produce their shots at a record pace, WSJ reports.While new mRNA technology makes industrialization easier than a traditional vaccine - since manufacturers do...